Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system.
- Author:
Min MIN
1
;
Li LIN
;
Cheng-Feng BI
;
Xiao-Qing WANG
;
Tian-You LUO
;
Sha ZHAO
;
Wen-Yan ZHANG
;
Wei-Ping LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adaptor Proteins, Signal Transducing; metabolism; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Central Nervous System Neoplasms; classification; metabolism; pathology; therapy; Cyclophosphamide; therapeutic use; Doxorubicin; therapeutic use; Female; Follow-Up Studies; Forkhead Transcription Factors; metabolism; Humans; Immunophenotyping; methods; Interferon Regulatory Factors; metabolism; Ki-67 Antigen; metabolism; LIM Domain Proteins; metabolism; Lymphoma, Large B-Cell, Diffuse; classification; metabolism; pathology; therapy; Male; Methotrexate; therapeutic use; Middle Aged; Neoplasm Proteins; metabolism; Neprilysin; metabolism; Positive Regulatory Domain I-Binding Factor 1; Prednisone; therapeutic use; Prognosis; Proto-Oncogene Proteins; metabolism; Proto-Oncogene Proteins c-bcl-2; metabolism; Proto-Oncogene Proteins c-bcl-6; metabolism; Repressor Proteins; metabolism; Retrospective Studies; Serpins; metabolism; Survival Rate; Vincristine; therapeutic use; Young Adult
- From: Chinese Journal of Oncology 2012;34(2):110-116
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the subtypes of primary diffuse large B cell lymphoma of the central nervous system (CNS DLBCL) and to explore the relationship between the subtype classification and prognosis.
METHODSImmunohistochemical staining was used to determine the expression of CD20, CD3, CD10, Bcl-6, Mum-1, CD5, Bcl-2, Ki-67, FOXP-1, GCET-1, BLIMP-1 and LMO-2 antigens on paraffin-embedded sections of 47 cases. Hans, Choi and Tally subtypes were classified, and univariate and multivariate analyses were used to elucidate the relationship between the subtypes and prognosis.
RESULTSIn the 47 cases, the expression of Bcl-2 in the tumor cells was 46.8%, CD10 4.3%, Bcl-6 70.2%, Mum-1 53.2%, GCET-1 36.2%, BLIMP-1 4.3%, FOXP-1 63.8% and LMO-2 19.2%. The positive rate of Ki-67 was 30% to 95%, with a median of 80%, of which 12 cases (25.5%) was > or = 90%. The Hans subtype classification showed 16 cases (34.0%) were of GCB type and 31 cases (66.0%) of non-GCB type. The Choi subtype classification showed 16 cases (34.0%) were of GCB type and 31 cases (66.0%) of ABC type. The Tally subtype classification showed 6 cases (12.8%) were of GCB type and 41 cases (87.2%) of non-GCB type.
CONCLUSIONSThe results of this study show that there is no significant correlation between the three subtypes and prognosis. The prognosis is correated with post-operative radiotherapy, chemotherapy and MTX therapy.
